In the OPUS-TIMI 16 trial O'Donoghue M study, H-FABP was tested on 2, 287 ACS patients, the follow-up period was 10 months, the results showed that patients with elevated H-FABP had an increased risk of mortality (HR = 4.1, 95% CI 2.6 - 6.5), recurrent MI (HR = 1.6; 95% CI 1.0 - 2.5), decompensated heart failure (HR = 2.6, CI 95% 1.9 - 3.5).